The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
Abstract
Patients undergoing liver transplantation for hepatitis B-related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG). Antiviral therapy with lamivudine has proven effective in lowering hepatitis B virus (HBV) DNA and improving histology in patients with hepatitis B infection; its role in prophylaxis against hepatitis B recurrence following liver transplantation is under investigation. Viral breakthrough and resistance, however, are a significant problem with monotherapy with either HBIG or lamivudine. The efficacy of combination lamivudine/HBIG prophylaxis has not been reported. Fourteen patients underwent transplantation for decompensated liver disease owing to hepatitis B. Lamivudine (150 mg po/d) was begun before transplantation in 10 patients, including 4 who were HBV DNA-positive. In addition, 1 patient was HBV DNA-positive when transplanted. HBIG was given perioperatively and continued thereafter; treatment with lamivudine was maintained or initiated at the time of transplantation and continued indefinitely. The median follow-up was 387 days. Actuarial 1-year patient and graft survival was 93% (1 patient died of unrelated causes). At a median interval of 28 days following lamivudine treatment, all 5 HBV DNA-positive patients cleared HBV DNA from the serum; 1 went on to clear hepatitis B surface antigen (HBsAg), before transplantation, at day 148 of lamivudine treatment. By the highly sensitive polymerase chain reaction (PCR), at a median of 346 days (range, 130-525 days) following transplantation, all 13 surviving patients had no detectable serum HBV DNA. Lamivudine suppresses HBV replication in patients awaiting liver transplantation. At a median follow-up of 1.1 years, combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver Transplantation in European Patients with the Hepatitis B Surface Antigen
Samuel, D., Muller, R., Alexander, G., Fassati, L., Ducot, B., Benhamou, J.-P., & Bismuth, H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312163292503 · Cited by 1,031
Rehermann, B., Ferrari, C., Pasquinelli, C., & Chisari, F. V. (1996) · Nature Medicine · doi:10.1038/nm1096-1104 · Cited by 854
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332501 · Cited by 800
Tisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G. M., & Harrison, T. J. (1996) · Hepatology · doi:10.1002/hep.510240339 · Cited by 466
Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
Samuel, D., Bismuth, H., Bismuth, A., Arulnaden, J.-L., Mathieu, D., Reynes, M., Benhamou, J.-P., & Brechot, C. (1991) · The Lancet · doi:10.1016/0140-6736(91)92515-4 · Cited by 405
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
Grellier, L., Mutimer, D., Ahmed, M., Brown, D. J., Burroughs, A. K., Rolles, K., McMaster, P., Beranek, P. A., Kennedy, F., Kibbler, H., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04444-3 · Cited by 391
Terrault, N. A., Zhou, S., Combs, C., Hahn, J. A., Lake, J. R., Roberts, J. P., Ascher, N. L., & Wright, T. L. (1996) · Hepatology · doi:10.1002/hep.510240601 · Cited by 301
Protzer-Knolle, U., Naumann, U., Bartenschlager, R., Berg, T., Hopf, U., zum Büschenfelde, K.-H. M., Neuhaus, P., & Gerken, G. (1998) · Hepatology · doi:10.1002/hep.510270138 · Cited by 271
Liver transplantation in HBs antigen (HBsAg) carriers
Müller, R., Gubernatis, G., Farle, M., Niehoff, G., Klein, H., Wittekind, C., Tusch, G., Lautz, H.-U., Böker, K., Stangel, W., et al. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90869-d · Cited by 190
Cited by
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease
Singal, A. K., Guturu, P., Hmoud, B., Kuo, Y.-F., Salameh, H., & Wiesner, R. H. (2013) · Transplantation · doi:10.1097/tp.0b013e31827afb3a · Cited by 278
Metadata
- Authors
- Markowitz, J. S., Martin, P., Conrad, A. J., Markmann, J. F., Seu, P., Yersiz, H., Goss, J. A., Schmidt, P., Pakrasi, A., Artinian, L., Murray, N. G., Imagawa, D. K., Holt, C., Goldstein, L. I., Stribling, R., & Busuttil, R. W.
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 585-589
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2091910482
- Cited by
- 485
- References
- 15
- FWCI
- 32.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. https://app.cochat.ai/papers/10.1002/hep.510280241
- The paper
- Markowitz, J. S., Martin, P., Conrad, A. J., Markmann, J. F., Seu, P., Yersiz, H., Goss, J. A., Schmidt, P., Pakrasi, A., Artinian, L., Murray, N. G., Imagawa, D. K., Holt, C., Goldstein, L. I., Stribling, R., & Busuttil, R. W. (1998). Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. https://doi.org/10.1002/hep.510280241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
